Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver-Reference-Cited by-同舟云学术

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver

Published:2012-08-14 Issue:10 Volume:32 Page:1477-1492
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Leroy Vincent¹,Serfaty Lawrence²,Bourlière Marc³,Bronowicki Jean-Pierre⁴,Delasalle Patrick⁵,Pariente Alexandre⁶,Pol Stanislas⁷,Zoulim Fabien⁸,Pageaux Georges-Philippe⁹

Affiliation:

1. Centre de Recherche INSERM-UJF U823; Institut Albert Bonniot et Clinique Universitaire d'Hépato-Gastroentérologie; Pôle Digidune, CHU; Grenoble; France

2. Service d'Hépatologie; Hôpital Saint-Antoine; INSERM UMRS 938, Faculté de Médecine Saint-Antoine, Assistance Publique des Hôpitaux de Paris, Université Pierre & Marie Curie; Paris; France

3. Service d'hépato-gastroentérologie; Hôpital Saint-Joseph; Marseille; France

4. Service d'hépato-gastroentérologie; CHU de Nancy; Vandoeuvre-les-Nancy; France

5. Cabinet d'hépato-gastroentérologie; Grasse; France

6. Service d'hépato-gastroentérologie; Hôpital; Pau; France

7. Université Paris Descartes, Unité d'Hépatologie; Assistance Publique des Hôpitaux de Paris, Hôpital Cochin et INSERM U1016; Paris; France

8. INSERM U1052, et Université Lyon 1; Lyon; France

9. Service d'Hépato-Gastroentérologie et Transplantation Hépatique; Centre Hospitalier Universitaire Saint Eloi; Montpellier; France

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1478-3231.2012.02856.x/fullpdf

Reference41 articles.

1. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors;Meffre;J Med Virol,2010

2. The availability of direct acting antivirals in 2012: a French model based analysis of the increased number of patients treated for chronic HCV infection;Deuffic-Burban;Gut,2012

3. HCV burden in Europe: impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach;Deuffic-Burban;J Hepatol,2011

4. Traitement de l'hépatite C;Conférence de consensus;Gastroenterol Clin Biol,2002

5. EASL Clinical Practice Guidelines: management of hepatitis C virus infection;Craxi;J Hepatol,2011

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation;Transplantation;2018-01

2. Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study;American Journal of Transplantation;2017-10-19

3. Sociodemographic Determinants of Waitlist and Posttransplant Survival Among End-Stage Liver Disease Patients;American Journal of Transplantation;2017-08-12

4. Les nouvelles stratégies antivirales dans l’hépatite C en 2017;Revue Francophone des Laboratoires;2017-04

5. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUPILT study;Journal of Hepatology;2016-10